1/2 phase Lorlatinib trial
Solomon BJ et al, Lorlatinib in patients with ALK+ NSCLC: results from a global phase 2 study, Lancet Oncol. Dec 2018; 12:1654-1667.
CROWN interim analysis
Shaw AT et al, First-line Lorlatinib or crizotinib in advanced ALK-positive lung cancer, N Engl J Med. Nov 2020; 383: 2018-2029.
CROWN 3Y follow up
Solomon BJ et al, Efficacy and safety of 1L Lorlatinib versus crizotinib in patients with ALK+ NSCLC: updated analysis of data from phase 3, randomized, open label CRPWN study, Apr 2023; 11(4): 354-366.
Lorlatinib Intracranial Efficacy and Safety Post Hoc analysis
Solomon BJ et al. Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK+ aNSCLC From the Phase III CROWN Study. J Clin Oncol. 2022 Nov ;40 (31):3593-3602
CROWN trial updated 5 Years outcomes
Solomon BJ et al., Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study, J Clin Oncol. 2024 in press.
